Cancer Res Treat.  2024 Apr;56(2):549-556. 10.4143/crt.2023.1109.

Assessment of Eligibility and Utilization of Accelerated Partial Breast Irradiation in Korean Breast Cancer Patients (KROG 22-15)

• Chun SJ
• Jo JH
• Kim YB
• Park S
• Ahn SJ
• Kim SS
• Kim K
• Shin KH

• KMID: 2554344
• DOI: http://doi.org/10.4143/crt.2023.1109

Abstract

Purpose
We investigated the proportions of patients eligible for accelerated partial breast irradiation (APBI) among those with pT1-2N0 breast cancer, based on the criteria set by the American Society for Radiation Oncology (ASTRO), the Groupe Européen de Curiethérapie and the European Society for Radiotherapy and Oncology (GEC-ESTRO), the American Brachytherapy Society (ABS), and the American Society of Breast Surgeons (ASBS). Additionally, we analyzed the rate of APBI utilization among eligible patients.
Materials and Methods
Patients diagnosed with pT1-2N0 breast cancer in 2019 were accrued in four tertiary medical centers in Korea. All patients had undergone breast conserving surgery followed by radiotherapy, either whole breast irradiation or APBI. To determine which guideline best predicts the use of APBI in Korea, the F1 score and Matthews Correlation Coefficient (MCC) were determined for each guideline.
Results
A total of 1,251 patients were analyzed, of whom 196 (15.7%) underwent APBI. The percentages of eligible patients identified by the ASTRO, GEC-ESTRO, ABS, and ASBS criteria were 13.7%, 21.0%, 50.5%, and 63.5%, respectively. APBI was used to treat 54.4%, 37.2%, 27.1%, and 23.7% of patients eligible by the ASTRO, GEC-ESTRO, ABS, and ASBS criteria, respectively. The ASTRO guideline exhibited the highest F1 score (0.76) and MCC (0.67), thus showing the best prediction of APBI utilization in Korea.
Conclusion
The proportion of Korean breast cancer patients who are candidates for APBI is substantial. The actual rate of APBI utilization among eligible patients may suggest there is a room for risk-stratified optimization in offering radiation therapy.

Keyword

Early breast cancer; Radiotherapy; Accelerated partial breast irradiation; APBI guidelines

Figure

• 

  Fig. 1. The F1 score and Matthew Correlation Coefficient to each guideline. ABS, American Brachytherapy Society; ASBS, American Society of Breast Surgeons; ASTRO, American Society for Radiation Oncology; GEC-ESTRO, Groupe Européen de Curiethérapie and the European Society for Radiotherapy and Oncology; MCC, Matthew correlation coefficient.

Reference

References

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast cancer [Internet]. Plymouth Meeting, PA: National Comprehensive Cancer Network;2023. [cited 2023 May 5]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

2. Park YH, Senkus-Konefka E, Im SA, Pentheroudakis G, Saji S, Gupta S, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Ann Oncol. 2020; 31:451–69.

3. Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019; 394:2165–72.

4. Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019; 394:2155–64.

5. Strnad V, Polgar C, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, et al. Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. Lancet Oncol. 2023; 24:262–72.

6. Meattini I, Marrazzo L, Saieva C, Desideri I, Scotti V, Simontacchi G, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence Trial. J Clin Oncol. 2020; 38:4175–83.

7. Anderson B, Arthur D, Hannoun-Levi JM, Kamrava M, Khan A, Kuske R, et al. Partial breast irradiation: an updated consensus statement from the American Brachytherapy Society. Brachytherapy. 2022; 21:726–47.

8. Consensus guideline on accelerated partial breast irradiation. Columbia, MD: The American Society of Breast Surgeons;2018.

9. Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol. 2017; 7:73–9.

10. Polgar C, Van Limbergen E, Potter R, Kovacs G, Polo A, Lyczek J, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol. 2010; 94:264–73.

11. Manyam BV, Tendulkar R, Cherian S, Vicini F, Badiyan SN, Shah C. Evaluating candidacy for hypofractionated radiation therapy, accelerated partial breast irradiation, and endocrine therapy after breast conserving surgery: a Surveillance Epidemiology and End Results (SEER) analysis. Am J Clin Oncol. 2018; 41:526–31.

12. Balagamwala EH, Manyam BV, Leyrer CM, Karthik N, Smile T, Tendulkar RD, et al. Most patients are eligible for an alternative to conventional whole breast irradiation for early-stage breast cancer: a national cancer database analysis. Breast J. 2018; 24:806–10.

13. Kang SY, Lee SB, Kim YS, Kim Z, Kim HY, Kim HJ, et al. Breast cancer statistics in Korea, 2018. J Breast Cancer. 2021; 24:123–37.

14. Jeong JU, Yoon JH, Park MH, Yoon MS, Song JY, Nam TK, et al. A phase I/II trial to evaluate the technical feasibility of partial breast irradiation with three-dimensional conformal radiation therapy in Korean women with stage I breast carcinoma: an initial report of the Korean Radiation Therapy Oncology Group (KROG) Study 0804. Cancer Res Treat. 2015; 47:18–25.

15. Chicco D, Jurman G. The advantages of the Matthews correlation coefficient (MCC) over F1 score and accuracy in binary classification evaluation. BMC Genomics. 2020; 21:6.

16. Renton SC, Gazet JC, Ford HT, Corbishley C, Sutcliffe R. The importance of the resection margin in conservative surgery for breast cancer. Eur J Surg Oncol. 1996; 22:17–22.

17. Bundred JR, Michael S, Stuart B, Cutress RI, Beckmann K, Holleczek B, et al. Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis. BMJ. 2022; 378:e070346.

18. Yoon TI, Lee JW, Lee SB, Sohn G, Kim J, Chung IY, et al. No association of positive superficial and/or deep margins with local recurrence in invasive breast cancer treated with breast-conserving surgery. Cancer Res Treat. 2018; 50:275–82.

19. McIntosh A, Freedman G, Eisenberg D, Anderson P. Recurrence rates and analysis of close or positive margins in patients treated without re-excision before radiation for breast cancer. Am J Clin Oncol. 2007; 30:146–51.

20. Mullen R, Macaskill EJ, Khalil A, Elseedawy E, Brown DC, Lee AC, et al. Involved anterior margins after breast conserving surgery: is re-excision required? Eur J Surg Oncol. 2012; 38:302–6.

21. Park HJ, Kim K, Kim YB, Chang JS, Shin KH; Division for Breast Cancer, Korean Radiation Oncology Group. Patterns and longitudinal changes in the practice of breast cancer radiotherapy in Korea: Korean Radiation Oncology Group 22-01. J Breast Cancer. 2023; 26:254–67.

22. Lee HI, Kim K, Kim JH, Chang JH, Shin KH. The acute and late toxicities of MRI-guided external beam partial breast irradiation delivered using a once-per-day regimen. Front Oncol. 2021; 11:649301.

23. Byun HK, Chang JS, Kim H, Kim J, Han MC, Kim SY, et al. Cosmetic outcome and toxicity after stereotactic accelerated partial breast irradiation in early breast cancer: a prospective observational cohort study. Int J Radiat Oncol Biol Phys. 2023; 117:690–700.

24. Gregucci F, Fozza A, Falivene S, Smaniotto D, Morra A, Daidone A, et al. Present clinical practice of breast cancer radiotherapy in Italy: a nationwide survey by the Italian Society of Radiotherapy and Clinical Oncology (AIRO) Breast Group. Radiol Med. 2020; 125:674–82.

25. Moon SH, Shin KH, Kim TH, Yoon M, Park S, Lee DH, et al. Dosimetric comparison of four different external beam partial breast irradiation techniques: three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, helical tomotherapy, and proton beam therapy. Radiother Oncol. 2009; 90:66–73.